1. Home
  2. ASTC vs IMNN Comparison

ASTC vs IMNN Comparison

Compare ASTC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrotech Corporation (DE)

ASTC

Astrotech Corporation (DE)

N/A

Current Price

$7.64

Market Cap

14.5M

Sector

Industrials

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$1.42

Market Cap

7.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASTC
IMNN
Founded
1984
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5M
7.9M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
ASTC
IMNN
Price
$7.64
$1.42
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $10.00
AVG Volume (30 Days)
26.8K
★ 127.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 2600.00
N/A
EPS
★ 0.25
N/A
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$28.62
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.92
$1.30
52 Week High
$68.85
$5.55

Technical Indicators

Market Signals
Indicator
ASTC
IMNN
Relative Strength Index (RSI) 52.66 44.10
Support Level $6.80 N/A
Resistance Level $7.71 $1.75
Average True Range (ATR) 0.54 0.13
MACD 0.15 0.00
Stochastic Oscillator 82.78 28.89

Price Performance

Historical Comparison
ASTC
IMNN

About ASTC Astrotech Corporation (DE)

Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: